Cell Therapy Market Status and Size Report 2030 The Daily Vale – The Daily Vale

Theglobal cell therapy marketsize was valued atUSD 8.1 billion in 2021and is estimated to reachUSD 23.9 billion by 2030, growing at a CAGR of 14.5% over the forecast period. The development of precision medicine and advancements in cellular therapies in context to their efficiency & manufacturing are expected to be major drivers for the market. Moreover, the development of stem cell banking facilities and resultant enhancement of stem cells production, storage, and characterization are also expected to improve the volumetric capabilities of the market at a global level, which is anticipated to directly translate into revenue for this market at a larger level. Ongoing technological advancements in the parent and ancillary markets for stem and non-stem cells usage are expected to reinforce the demand over the forecast period. There are fewer commercialized cellular therapy products in the current market than the number of research products. This is partly due to stringent regulations and the high cost of stem cells.

Cell lines, such as Induced Pluripotent Stem Cells (iPSC) and human Embryonic Stem Cells (hESC) are recognized as having high growth potential; as a result, many research entities and companies are making significant investments in R&D pertaining to iPSC- and hESC-derived products.

Pricing of stem cell transplantation varies from region to region. For instance, the cost of transplantation in the U.S. is higher than that in Germany or China. In March 2018, Alofisel by TiGenix received approval for marketing in Europe. This was the first allogeneic stem cell therapy to be approved in Europe. Furthermore, revenue for certain products varies for the country; for instance, products like INVOSSA received approval for marketing in Korea but have yet to receive marketing authorization in the U.S. Growth is also influenced by the commercialization of unauthorized stem cell treatments revenue generation.

Get PDF for more Professional and Technical insights:https://www.marketstatsville.com/request-sample/cell-therapy-market

Global Cell Therapy Market Definition

Therapy in which viable cells are injected, grafted, or implanted into a patient to effectuate a medicinal effect is known ascell therapy; for instance, In immunotherapy, T-cells capable of fighting cancer cells via cell-mediated immunity are transplanted, and stem cells are grafted to regenerate diseased tissues.

Cellular therapies hold a great therapeutic promise across various clinical applications. This has resulted in substantial global investments in research and their clinical translation. Rapid advances in stem cell research have the potential to fulfill the unmet demand of pharmaceutical entities, biotech entities, and doctors in disease management. Several unknown therapies are in clinical development.

Furthermore, government and private funding agencies are constantly offering grants to support projects at various stages of clinical trials, increasing the number of ongoing clinical trials.

Research on human embryonic stem cells is ethically controversial. Harvesting embryonic stem cells involves the destruction of human embryos, raising a moral concern. In addition, stringent regulations for obtaining Intellectual Property Rights (IPR) for products or materials used in research are major restraints for commercializing these services. Ethical approval should be obtained to store cell lines and tissues in biorepositories to avoid the usage of tissue for illegal purposes or to identify proxy diseases to claim insurance. Moreover, controversies surrounding the use of embryonic stem cells for research impede the market growth in several regions

You Can Purchase Complete[emailprotected]https://www.marketstatsville.com/buy-now/cell-therapy-market?opt=2950

The study categorizes the cell therapy market based on use type and therapy type at the regional and global levels.

The analysis of the cell therapy market is based on the use of stem cells for clinical and research purposes. The research-use segment dominated the market for the global cell therapy market and accounted for the largest revenue share of 58.3% in 2021. Currently, cell therapies (stem & non-stem cells) are majorly being used for research projects, which in turn, has led to a large revenue share of this segment in 2021. Cell-based therapies are all possibilities for the replacement, repair, restoration, and regeneration of damaged tissues, cells, and organs. As an alternative to traditional treatment strategies, researchers are investing heavily in developing effective and safe cell-based treatments.

Access full Report Description,TOC, Table of Figure, Chart, etc.@https://www.marketstatsville.com/table-of-content/cell-therapy-market

As per the CGT Catapult database of clinical trials, 59 cell and gene therapy trials are ongoing in the UK. Out of all therapeutic areas, oncology has the highest number of ongoing clinical trials. T cells, CD34+ and CD133+ stem cells, mesenchymal stem/stromal cells are some predominantly employed cell types for clinical investigation. Neural cells, bone marrow mononuclear cells, fibroblasts, cornea cells, antigen-presenting cells, epithelial cells, and chondrocytes are some other cells that are being explored for the development of cell therapies.

Asia Pacificaccounts for the highestCAGR during the forecast period

Based on the regions, the global cell therapy market has been segmented across North America, AsiaPacific, Europe, South America, and the Middle East & Africa.In the Asia Pacific, the market for cell therapy is anticipated to witness a lucrative growth rate of 15.5% over the forecast period. Advancements in stem cell therapy in Asian countries are observed to be better than those in the U.S. This has resulted in Asia leading stem cell research. Several stem cell consortiums in Asian countries aim to ensure coordinated and focused R&D programs. Moreover, patients from western countries migrate to Asian countries for treatment, owing to the flexible legal framework.

Companies from Japan, South Korea, India, China, Taiwan, Singapore, and the rest of Asia were active participants in the conference. In addition, the large regional population and untapped potential present in the region have resulted in global firms entering the market. Moreover, this region offers relatively inexpensive manufacturing & operating units for conducting research. These factors are expected to play a major role in expanding the stem cell market in this region.

Request For Report Description @https://www.marketstatsville.com/cell-therapy-market

The cell therapy market is mildly concentrated in nature with few numbers of global players operating in the market such as Kolon TissueGene, Inc., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., Castle Creek Biosciences, Inc., MEDIPOST, Osiris Therapeutics, Inc., PHARMICELL Co., Ltd, Tameika Cell Technologies, Inc., Cells for Cells, NuVasive, Inc., Vericel Corporation, and Celgene Corporation

Continue reading here:
Cell Therapy Market Status and Size Report 2030 The Daily Vale - The Daily Vale

City of Hope to buy Cancer Treatment Centers of America for $390M – Modern Healthcare

City of Hope, a prominent not-for-profit cancer researcher and treatment provider, said Wednesday it plans to buy Cancer Treatment Centers of America.

The deal, expected to close early next year pending regulatory approval, would create a large network of inpatient and outpatient oncology care that would serve an estimated 115,000 patients annually. The definitive agreement holds that Duarte, California-based City of Hope would pay $390 million for CTCA, based in Boca Raton, Florida.

"In Cancer Treatment Centers of America, we found an organization that shares with us that nonnegotiable value of putting patients first, the urgency of eliminating cancer and the commitment to delivering high-quality care," City of Hope CEO Robert Stone said in an interview.

The transaction would unite two cancer specialists with decidedly different backgrounds. City of Hope is among 71 National Cancer Institute-designed cancer centers in the country. It's a distinction the federal agency grants to providers that meet rigorous standards for state-of-the-art research focused on improving cancer prevention, diagnosis and treatment. City of Hope is known as a leading cancer researcher, with more than 450 patent portfolios and 95 active investigator-initiated drugs. The provider also runs a large bone marrow and stem cell transplant program.

Dr. Pat Basu, CTCA's CEO, said in an interview he looks forward to granting CTCA's patients access to City of Hope's clinical trials and bone marrow transplant program, which he said is the best in the country. Together, Basu said he thinks the providers will speed up important milestones in cancer research and treatment outcomes.

"Strategically, this a remarkably complementary fit," he said, noting there is no geographic overlap between the providers.

CTCA is a for-profit company with hospitals and outpatient clinics in three metro areas: Atlanta, Chicago and Phoenix. The company sold its hospitals in Philadelphia and Tulsa, Oklahoma earlier this year and has touted a focus on partnerships with health systems that rely heavily on telehealth.

CTCA spent the decade ending in 2016 operating under a federal injunction that barred the company from making unsubstantiated claims in its advertising. The Federal Trade Commission accused CTCA of making false claims regarding its success rates. CTCA cherry-picked patients based on insurance coverage and overhyped the success of its treatments, according to a 2013 Reuters investigation.

"I'm not concerned," Stone said when asked about CTCA's reputation. "I focus more on, frankly: What is it the cancer patients want? Cancer patients want timely access to doctors focused on treating their type of cancer."

City of Hope performed thorough due diligence into CTCA, and Stone said he personally visited the company's facilities in Atlanta and Phoenix. Stone's team emerged convinced that the two companies share the same values, Stone said.

Once the combination is official, City of Hope said it plans to transform CTCA into a not-for-profit organization. Basu will remain CEO of CTCA and will report to Stone. Stone said his team hasn't decided whether they'll pursue NCI designation for CTCA.

The broader goal behind the deal is to make cancer care available to more people, Stone said. Eighty percent of cancer care is currently delivered in community settings, but there's a widening gap between those who get access and those who don't, he said. The combined company would have 575 physicians and more than 11,000 employees across five states.

The deal would expand City of Hope's geographic reach. Its 36 care sites are currently limited to Southern California, in addition to a genomics institute it recently acquired in Phoenix.

Both providers partner directly with employers to offer workers cancer information and support. To that end, City of Hope launched its AccessHope program in 2019, and it now includes 17 Fortune 500 companies.

City of Hope posted a 2.7% operating margin in the nine months ended June 30, up from 0% in the prior-year period. Significant investment income pushed its excess margin to 27% in the 2021 period, when it made almost $700 million on about $2.6 billion in revenue.

As a private, for-profit company, CTCA is not required to disclose information on its financial performance.

Rumors have swirled about a potential CTCA sale since a 2020 report that the company was considering a private equity buy-out. Basu acknowledged there were other potential partners that expressed interest, but said City of Hope is more aligned with CTCA's mission and strategy.

Wednesday's news follows other deal action in the cancer treatment space. Last month, the first publicly traded oncology specialist debuted on the stock market following its merger with a special purpose acquisition company. The Oncology Institute, headquartered in the Los Angeles area, has 50 offices in four states and touts a value-based model of oncology care.

While City of Hope brings cutting-edge research and clinical trials to the table, Basu said CTCA brings a national oncology footprint and a recognizable brand.

"Ultimately I think this is tremendous for patients, it's tremendous for our collective organizations and outstanding for our employees on both sides," he said.

Read more here:
City of Hope to buy Cancer Treatment Centers of America for $390M - Modern Healthcare

The lung game: is hyperbaric oxygen therapy any good? – Financial Times

We typically breathe 25,000 times aday. And were right to be worried about the quality of the air were inhaling. Weve long been concerned about pollution in citiesand Covid has made us focus ever more closely on whats in the air. But is there anywhere or anything we can breathe with impunity? Widely used by athletes, hyperbaric oxygen therapy is linked to benefits ranging from wound healing and long Covid recovery, to improved immunity andbrain function, andeven cellular youth. Footballers Mohamed Salah and Cristiano Ronaldo are fans, as are Michael Phelps and LeBron James and Justin Bieber. Soshould we all sign up?

In HBOT a patient breathes 100 per cent oxygen inapressurised chamber, says Dr Gary Smerdon, CEO ofDDRC Healthcare, a UK-based medical charity that researches diving diseases and provides hyperbaric treatment. The pressure causes the oxygen to dissolve into your blood plasma, he explains; it thereby drives 1,200per cent more oxygen into circulation. A typical solo chamber is a cylindrical pod a bit bigger than an old-school sunbed; its a comfortable enough experience, beyond a slight ear-popping, though not one for the claustrophobic.

Claimed benefits include a lowering of inflammation, aboost in the production of energy in cells throughout the body (via the ATP molecule), an eightfold increase instem-cell circulation (key for repair), enhanced immune function and the formation of new blood vessels. But who derives most from the treatment? Thats controversial. The US Food and Drug Administration and the European Committee of Hyperbaric Medicine have approved 13 conditions for treatment, such as decompression sickness (aka the bends) and non-healing wounds. DDRC Healthcare also treats certain off-label conditions, such asinjuries in professional rugby players. With HBOT, damaged ligaments heal with a more flexiblecollagen, says Smerdon. Some of the UKs leading chambers are designed for racehorses. Given that thebest results start after 20 to 80 hours worth of treatments (which each cost 250), then, says Smerdon, If you are only a weekend warrior, I would say the gainsare too marginal to be worth it.

When it comes to treating long covid, Smerdon says initial findings show promise, but regarding conditions such as ME or fatigue, or using HBOT as an anti-ageing, pro-health hack, he is cautious: Caveat emptor. It may help, but there is no clearly defined evidence. At the same time, he shrugs, getting hard data is challenging, because running the trials is difficult and really expensive. While all the doctors I speak to concur is that HBOT should be done under proper medical supervision (contraindications include certain lung issues) and not simply, says Smerdon, by some high-street beautician, a growing number of unregulated chambersare appearing in the UK.

Do your research and go in with your eyes open

Dr Nur Ozyilmaz is a paediatric consultant who has worked at Kings College Hospital and Great Ormond Street. Her belief in integrative medicine (combining conventional and complementary therapies) has led her to found Numa, a sleek, white hyperbaric centre off Bond Street in London. Each patient is assessed to seeifthey would benefit from treatment; they can present with anything from brain injury to inflammatory bowel disease, and Ozyilmaz has also seen so-called biohackers seeking optimised health and enhanced performance: More and more young City workers come wanting to perform better at work, and often also in sports. Typically they have 20 sessions close together (a 90-minute treatment is 240), then two a week. Iused to discourage them, saying there is no evidence for this kind of approach. It could all be placebo, but they swear it improves their energy levels, sleep and exercise capacity.

Far more patients come with a history of concussion, which has left them with issues such as hormonal imbalances or fatigue, she continues. I am passionate about treating them, as we see such good results. We also see patients with brain fog associated with long Covid, most of whom start reporting improvements from their first few sessions.

Numa will also administer HBOT to older CEOs hoping to sharpen their thinking. This autumn has seen a fresh flurry of interest around HBOT and dementia, with new research concluding it offers multifaceted neuro-protective effects that improve memory and brain function by boosting blood flow and slowing the growth of amyloid plaques in the brain, thought to be connected to Alzheimers. This builds on other studies, such as one that found HBOT induced cognitive enhancements... including information-processing speed and executive functions.

However, says Dr Gary Toups, head of hyperbaric medicine at the Mayo Clinic in Rochester, Minnesota, Ive not seen any significant effect on cognition in patients treated with HBOT. Along with Smerdon, he says more research is needed to investigate whether HBOT may slow down cellular ageing: a widely publicised Israeli study suggested it might, finding that the length of telomeres (the protective caps over the end of our chromosomes, which diminish as we age) increased by more than 20 per cent over a 60-day treatment, and damaging, senescent zombie cells decreased by up to 37 per cent. So far, he says, it is only a single study, the importance of which has yet to be determined.

Do your research and go in with your eyes open, says Smerdon. In off-label treatments, some people get excellent results; for others theres no effect. Ozyilmaz is more optimistic. What excites me about HBOT is the huge potential it offers without drugs or side effects, she says. It looks to a future of medicine where we can harness our bodys own ability to repair and regenerate, to support ourselves to optimal health.

Original post:
The lung game: is hyperbaric oxygen therapy any good? - Financial Times

Cell Culture Media Market is predicted to grow from US$ 2.6 Bn in 2020 to over US$ 5.6 Bn by 2031 – PRNewswire

Demand for cell culture media is increasing with rising production of biopharmaceuticals. Biopharmaceutical drugs are structurally similar to human compounds. This similarity in structure gives biopharmaceuticals the ability to cure diseases rather than only treat the symptoms. Also, biopharmaceuticals have fewer side effects because of their specificity, unlike conventional drugs that affect multiple systems. Biopharma is helping doctors in treating various diseases such as diabetes and cancer, because it allows clinicians to give specialized treatment to the specific medical problems of each patient.

With increasing demand for regenerative medicines, sale of cell culture media also increases. It is because regenerative medicine is that branch of medicine that develops methods to regrow, heal or replace injured or unhealthy cells, organs, and tissues.

Request for sample PDF of report: https://www.persistencemarketresearch.com/samples/31338

Key Takeaways from Market Study

"Increasing production of antibodies for treatment of diseases and rising prevalence of cancer are expected to drive demand of cell culture media over the decade," says a Persistence Market Research analyst.

Get Full TOC of the report: https://www.persistencemarketresearch.com/market-research/cell-culture-media-market/toc

Who is Winning?

Some of the chief manufacturers of cell culture media are focusing on product launches, collaborations, and acquisitions for global expansion objectives, thereby enhancing their market presence.

Key market players covered in this research include GE Healthcare, Thermo Fisher Scientific, Merck KGaA, Lonza, Corning Incorporated, Irvine Scientific, STEMCELL Technologies Inc., and PAN Biotech.

Get Full access of report: https://www.persistencemarketresearch.com/checkout/31338

Want More Valuable Insights?

Persistence Market Research brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global cell culture media Market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

The study provides compelling insights into the cell culture media market. The market is segmented into five parts based on product (serum containing media, serum-free media, protein free media, and chemically defined media) based on application (cancer research, biopharmaceuticals, regenerative medicine & tissue engineering, stem cell technologies, and others) based on the end user (biopharmaceutical companies, clinical research organizations, and academic research centers), and across seven major regions.

Related Reports:

o Cell Tissue Culture Supplies Marketo Stem Cell Therapy Marketo 3D Cell Cultures Market

About Persistence Market Research:

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

Overview:

Persistence Market Research is always way ahead of its time. In other words, it tables market solutions by stepping into the companies'/clients' shoes much before they themselves have a sneak pick into the market. The pro-active approach followed by experts at Persistence Market Research helps companies/clients lay their hands on techno-commercial insights beforehand, so that the subsequent course of action could be simplified on their part.

ContactRajendra Singh Persistence Market Research U.S. Sales Office: 305 Broadway, 7th Floor New York City, NY 10007 +1-646-568-7751 United States USA - Canada Toll-Free: 800-961-0353 Email: [emailprotected] Visit Our Website:https://www.persistencemarketresearch.com

SOURCE Persistence Market Research Pvt. Ltd.

Go here to see the original:
Cell Culture Media Market is predicted to grow from US$ 2.6 Bn in 2020 to over US$ 5.6 Bn by 2031 - PRNewswire

COVID: How bad is the omicron variant? Q&A on what new research is telling us – The Denver Post

The new omicron variant is spreading fast. But research is beginning to catch up.

Because an early case was detected in San Francisco, local scientists have quickly started growing the virus in high-security labs at UC San Francisco, UC Berkeley and Stanford.

Using cell cultures, theyll soon learn how readily it transmits, whether it can dodge our defenses and outcompete delta. In mice, theyll study whether it produces illness that is severe or mild.

In one or two weeks, we will have a much clearer picture of what this variant is going to do to us, said Dr. Melanie Ott of UC San Franciscos Gladstone Institute of Virology and Immunology.

Meanwhile, South Africa studies have begun to offer a real-world glimpse of how much risk omicron poses.

The extent to which omicrons sudden spread is caused by immune evasion or more contagiousness or both is yet unclear. But as the variant expands into 17 U.S. states and at least 45 nations worldwide, heres what were learning:

Q: Is omicron more or less dangerous than delta?

A: A new small study suggests that omicron may cause less severe illness than previous variants like delta.

The best indicator of disease severity is the in-hospital death rate. A report this weekend identified 10 omicron-linked hospital deaths at two South African hospitals, representing about 6% of 166 COVID-related admissions. This compared to a 17% death rate at the hospitals among COVID-19 patients during previous waves of infections. However, this time it wasnt just elders who died; four of the deaths were in adults ages 26 to 36.

The same hospital said that the majority of COVID patients did not need extra oxygen, and far fewer were so sick that they were admitted to the ICU. Most discovered they were infected only after being admitted to the hospital for other health reasons. The average hospital stay was only 2.8 days, down from 8.5 days during infection with other variants.

Most of these patients were unvaccinated, although there were some vaccinated admissions, as well.

Can this be generalized given the younger population in South Africa, with very extensive prior COVID? Thats an uncertainty that will remain until we see much larger numbers of infections in older people.

South African Medical Research Council

Q: Whats the latest guess about how infectious it is?

A: In South Africa, about 3 to 3.5 new omicron infections are estimated to stem from a single case. In contrast, the reproductive rate of delta in South Africa and the U.S. was about 1.5.

If omicrons reproductive rate continues at around 3, this indicates a much larger threat, in terms of case counts, than delta. The size of the wave depends on the susceptible population.

Trevor Bedford, Fred Hutchinson Cancer Research Center in Seattle

Q: Will omicron overtake delta?

A: In South Africa, omicron has surpassed delta as the dominant strain. But delta was on the wane there, so omicron had an open field to run in. Omicron did not have to push delta out.

What we dont know is how well omicron will compete in an environment thats 99.9% delta, such as California.

Dr. Warner Greene, Director of Gladstone Institute of Virology and Immunology, UCSF

Q: If it outcompetes delta, and its milder, isnt that good news?

A: It would be great if omicron is always a mild virus. But we dont know that yet. It will take a month or so to learn the virulence of this variant, and whether it will replace delta.

Dr. Warner Greene

Q: Will my previous infection protect me?

A: Perhaps not. South African doctors are seeing an uptick in reinfections among people who tested positive for the virus at least 90 days earlier, suggesting that immunity acquired through natural infection is not fully protective.

Omicron is three times more likely to cause reinfection compared to delta, according to a Dec. 2 paper.

Juliet Pulliam, director of the South African Centre for Epidemiological Modelling and Analysis, Stellenbosch University

Q: Are vaccines protective against infection?

A: We dont yet know. In infected patients in one very small South African study, more than half were considered fully vaccinated, with two shots.

But its unclear how much time had passed since their inoculation. If it was more than six months, their antibody levels had waned.

These patients hadnt gotten boosters. Boosting creates a huge increase in antibodies much more than what is achieved after the second vaccine dose. Thats what is leading vaccinologists to hope that even if antibody levels start to decline, protection will last longer. Its starting at a much higher level.

Dr. Warner Greene

Q: How long will it take to design omicron-specific vaccines?

A: Vaccine makers Pfizer and Moderna say they can get one ready within 100 days. Making a new mRNA vaccinewill involve generating a new genetic sequence, based on omicron, and encapsulating it in a fatty substance such as a lipid.

This autumn, the vaccine companies have been doing dry runs, practicing all aspects of executing a strain change the preclinical research, the manufacturing, the clinical testing and the regulatory submissions so they are ready to respond quickly.

Journal Nature

Q: Then will we have to wait for new clinical trials and FDA approval?

A: The FDA told the Wall Street Journal that it is already in conversations about streamlining authorization for revamped vaccines. Agency officials have met with vaccine makers and are working to set guidelines for the type of data that will be needed to swiftly evaluate the safety and efficacy of changes to current vaccines.

Wall Street Journal

Q: Should omicron change how we celebrate the holidays?

A: Its probably best to avoid international travel. Its far better to fly domestically than take a long haul flight to Europe, Asia or Africa. And be careful about where you fly domestically. Dont fly into a hot zone.

But experts like Dr. Greene say their perspective is so different this December versus last year. My family and I are vaccinated, he said. I do not believe that Im going to die of this coronavirus. I dont believe my family will die of this coronavirus.

Yes, I may get infected. I might be sick for awhile. But I am really confident that Im not going to die. And that just changes my whole perspective. Were in such a better place.

Dr. Warner Greene

Join our Facebook group for the latest updates on coronavirus in Colorado.

See the original post here:
COVID: How bad is the omicron variant? Q&A on what new research is telling us - The Denver Post

It is imperative to reduce the cost of cancer treatment: Ramesh Ramadurai, MD, 3M India – ETHealthworld.com

Shahid Akhter, editor, ETHealthworld, spoke to Ramesh Ramadurai, MD, 3M India, to know more 3M collaborations that can improve and impact cancer care, besides cutting down on the costs in a big way.

How has the technological and infrastructural facilities impacted Bone Marrow Transplantation in India ? Every year nearly 20,000 Indian patients, including many children, who suffer from blood and solid cancers require bone marrow transplantation (BMT). However, only 2,000 of these patients are fortunate enough to receive this therapy, as the cost of bone marrow transplantation can vary from INR 10 Lakhs to 30 Lakhs. It is imperative to reduce the cost of cancer treatment while maintaining a stringent focus on sterilization and quality. It is indeed the need of the hour for us to address this issue.

What are the various technological advancement required for the better functioning of the facilities?Despite the increasing demand for bone marrow transplantation, the number of bone marrow doners in India is astonishingly low. India conducts stem cell transplant procedure for approximately 2,000 every year, while around 80,000 to 100,000 annual transplants are required to tackle the burden of blood cancers and fatal blood disorders. Finding a matching donor is very difficult. This option is exercised only after the alternative options have failed.

India has only about 400,000 donors registered on the bone marrow registry. Chances of finding a donor match are as low as 10% to 15% compared to the West where the chances of matching are as high as 60% to 70% due to higher rates of donations.

What are the major and significant developments in treating bone marrow cancer in the country? A bone marrow registry collects information on individuals willing and able to donate bone marrow and gathers the donor information into a database. In India, organisations like Datri are helping to create a pool of donors to help people who do not have blood-related donors by finding an unrelated match for life-saving treatment.

Infusion of a memory cell is another advancement. This involves taking out the cells, sorting the good cells and the memory cells or the fighting cells, which can fight infections, sorting them out, capturing them and putting them back into the body after giving the requisite chemotherapy. This is also called T-cell depletion with memory cell infusion. It is now available in India and is affordable.

Through this partnership with United Way Bengaluru and Sri Shankara Cancer Hospital and Research Centre (SSCHRC), how does 3M aim to foster accessibility for people from different sections of the society in treating cancer. 3M India was brought into the SSCHRC family through United Way of Bengaluru, and this is our second round of engagement with the hospital. Last year, 3M India had donated equipment for cancer research and diagnostics like the Sanger sequencer and QPCR, made enhancements to the childrens play area at the long-stay Lakshmi Childrens center with child-friendly wall graphics, and provided kitchen utensils and cooking counters for the resident families of paediatric cancer patients.

We have donated several critical equipments for the research labs which contribute to the successful treatment of the BMT patients. As on date the BMT unit at SSCHRC has treated and discharged 5 patients and currently 4 are undergoing treatment. This wing of the hospital is accessible by few staff nurses and specialists like Dr K N Nataraj who is the Chief of Adult and Paediatric Haematology at the hospital. For a successful bone marrow transplantation, there are several requisites, some of which include, successful donor matching, extremely technique-sensitive harvesting and transplantation processes and robust infection control. With this essential, life-saving equipment, the cost of the treatment will reduce to approximately 50% (between Rs 8-12 Lacs as against the actual cost of Rs 15- 30 lacs) and help the hospital treat many more cancer patients.

How do 3M India and Sri Shankara Hospital plan to take this initiative ahead in the future for the growth and enhancement of bone marrow transplantation in the facility? It is matter of pride for 3M India and United Way of Bengaluru that we are associated with SSCHRC, an institution at the forefront of providing comprehensive cancer treatment to the needy, through CSR interventions.

By complying with the Foundation for the Accreditation of Cellular Therapy (FACT) Guidelines, the BMT Centre will be a one-of-a-kind medical facility where people of all economic status can receive treatment. Being a growing facility, the hospital is committed to continuing its responsibility towards expansion of multiple hospital beds and medical care. We are inspired by the commitment of the doctors and Sri Shankara Board of Trustees, led by Dr. B.S. Srinath and other dedicated professionals who developed a multifaceted approach to establishment a state of the art, affordable cancer hospital that is accessible to all irrespective of caste, creed, religion, gender or socioeconomic status.

Read the original:
It is imperative to reduce the cost of cancer treatment: Ramesh Ramadurai, MD, 3M India - ETHealthworld.com

Slidell mom with months to live, couldn’t afford to fight ‘very treatable’ cancer – WWLTV.com

They told me if I was going to have cancer, this is the one to have because it's very treatable. That gave me a lot of hope then, it wasn't going to be this bad.

SLIDELL, La. A Slidell mother in her late 40's, was hoping for a chance to try an experimental treatment to save her life, but she kept facing obstacles that now may have taken away her chances for survival.

It's a battle that many others in her situation face. They don't have access to the latest medical treatments.

Now the system continues to fail a cancer patient who is running out of time.

It's a moment in time most people might take for granted.Aparent sitting at the dining table helping a child with homework.But not for a single mom of three, NicoleHarris.

That is the hardest part. It's very hard. It breaks my heart. I feel like I'm failing them, Nicolle Harris, 49, said crying about her illness taking her away from her children.

It all started with back pain two years ago.Nicole was told it was arthritis.Several months went by.She started going down.

At that time I couldn't walk. I couldn't bathe myself. I couldn't do anything.

Then from blood work and a bone marrow biopsy,the long-awaited diagnosis.

I was terrified because it's cancer, said Harris.

Multiple Myeloma is a cancer of white blood cells called plasma cells. That's what fights infections by making antibodies.

They told me if I was going to have cancer, this is the one to have because it's very treatable. That gave me a lot of hope then, it wasn't going to be this bad, she remembers.

There was radiation, chemo, and a stem cell transplant. That failed immediately. Then more chemo, and more chemo, eight treatments in all. Then new hope, a clinical trial at MD Anderson in Houston. But soon those hopes vanished.

There's no way I could come up with that kind of money. I mean I'm sitting here with a treatment that could give me years right in my grasp, and I couldn't have it, Harris said through tears.

You see, Nicole is on Medicaid. Being this sick, she could no longer work cleaning houses with her friend. The initial assessment in Houston was nearly $40,000. Medicaid would not pay because it was out of state.

Through a chain of E-mails forwarded several times over, Medical Watch learned of Nicole's desperation. We reached out to the LSU Health Cancer Clinical Trials program.

The state of Louisiana has poorer outcomes than the rest of the country with respect to a variety of cancers, and much of this is due to access of care, explained Dr. John Stewart, Director of the LSU, LCMC Cancer Center.

Dr. Stewart has just come back to Louisiana for this position. His goal is to create a system that gets rid of health disparities in cancer care.

I think that it is unacceptable that a patient has to leave the state to get care for complex malignancies, and so one of the drivers for our cancer center is to offer state-of-the-art multidisciplinary care for cancer at home, said Dr. Stewart.

The Louisiana Cancer Research Center is already home to many national cancer clinical trials with the latest investigational treatments. Dr. Stewart wants to grow that program. And that's where hope was reborn for Nicole. LSU Health doctors lined her up with that same clinical trial in Houston, opening here in New Orleans.

That means the world to me. It gives me hope, like I have a chance to be with my kids for a little bit longer. Instead of three months, I could have three years, she said.

But just days ago, again shattered hopes. In the months-long delay, Nicole's plasma cell numbers have plummeted. Even though the clinical trial is now in her own backyard, she no longer qualifies for that new, investigational treatment. She is running out of time, and is already out of money.

I've been trying for a year and a half just to get disability. I haven't even been able to get that yet. I was approved medically, but not financially because all the stimulus payments were in my account, and so I had to start all over again and they said it could be five months or more, Harris lamented.

But if the doctors are right, she doesn't have five months. Multiple bones are breaking. There's excruciating pain. Nicole's mother has moved in to her Slidell home to care for her.

When asked what's getting her through this ordeal, she replied crying, My kids. Yeah, I don't want to leave them.

Her daughter says she gets sad sometimes and copes with alone time.

I will just I guess sit in my room and I guess hug a pillow, said fifth-grader, Alaina Harris.

It's driving her oldest, a senior in high school,and really the man of the house,to focus on grades and get into LSU,then to veterinary school.

When asked where does his resilience comes from, Damien Harris replied with a chuckle, My mom, and my Maw Maw. They're both hard workers.

And while she can watch her three children with tremendous pride,Nicole now waits for the last chance at hope.Doctors want to change her chemo medicine. It has a 10 percent chance of helping.

But for nearly two weeks, doctors have been waiting for Medicaid insurance approval. Two weeks: that's an eternity in Nicole's life.

Nicole now has lymphedema in her hip and leg. That is a build-up of fluid when the lymph system is blocked. The earliest a doctor from her original physicians office can see her, is two weeks from now.

Read the original post:
Slidell mom with months to live, couldn't afford to fight 'very treatable' cancer - WWLTV.com

What Are New Medical Solutions That Can Help Treat Patients? – iLounge

The biomedical field is constantly working to make new medical solutions that can help treat patients with various illnesses and conditions. Today, there are numerous medical solutions used today to help ease medical treatment for patients. These solutions include new medical devices, implants, software used to run medical equipment, and information technology systems.

The following are some of the most popular medical technologies that are used today:

Information technologies are another type of technology used today in medicine. For example, imaging systems let doctors examine patients like never before by allowing them to see inside a persons body without performing surgery first. One famous example of this type of medical solution is 3-D imaging software that uses pictures taken with an X-ray machine to give doctors a model to track health changes over time. Another example includes using information technology systems to control medical equipment or devices through smartphone computer programming or apps.

This type of technology allows doctors to use medical equipment with greater accuracy and helps make their work easier. For example, different types of imaging software help provide more transparent images for radiologists when they read X-rays and MRIs. This helps with making a diagnosis quicker. Thats why most hospitals would prefer to work with Wound Care, a web-based EHR tool. Such tools help record patient vitals and wound assessments to track each patients progress and provide better treatment.

These products can be used as medical solutions for people who want to check their health but dont want to visit a doctors office. Wearable health technologies include everything from smartwatches that measure heart rate and blood pressure functions to fitness trackers that help wearers monitor daily activity levels. Even Google has made its smart contact lenses that can track glucose levels for people with diabetes. However, these devices are designed specifically for individuals suffering from chronic diseases such as arthritis or Parkinsons disease in many cases.

Synthetic biology and genetic engineering tools are a technology used to treat illnesses or conditions that affect organs in the body. For example, if a patient has heart disease, they may need a new heart valve. In this case, doctors can use synthetic biology and genetic engineering tools to create a different kind of heart valve from those typically made from cow tissue. These valves have been tested on animals, and now researchers are testing them on humans as well.

Laboratory-grown organs are another medical solution used to help treat patients who need transplants for certain diseases or conditions that may have caused organ failure. A typical example is how stem cells taken from bone marrow can be turned into blood cells and then used to help treat patients with leukemia. Other types of laboratory-grown organs being tested in clinical trials today include partially functional livers and lungs grown from stem cells.

Medical equipment is another technology doctors can use when treating patients. For example, medical imaging devices like CT scanners and MRI machines help provide images of the bodys internal structures for diagnosis so doctors can see problems most other methods cannot detect. Another type of medical equipment includes surgical robots that can be moved by a computer program to perform surgery on a patient. This reduces the need for an incision since some procedures only require small openings or ones that heal very well without stitches or staples closing them up afterward.

Stem cells and stem cell therapies are a type of medical solution used to treat patients who have conditions that can be life-threatening or cause other severe complications. For example, patients with leukemia may need transplanted blood cells from healthy donors. In this case, doctors can use stem cells to develop those types of blood cells that will provide the best chance of curing the patients cancer without harming their body.

Other examples include using cord blood stem cells from newborns to make different kinds of healthy blood and immune system cells for older children and adults with certain diseases or using skin or other non-embryonic stem cells to make insulin-producing pancreatic beta cells for people diagnosed with diabetes Type 1.

Overall, biomedical technologies have been beneficial in making it easier for doctors to diagnose and treat their patients. Thanks to these technologies, many patients can live long, healthy lives with their illnesses or conditions under control. As technology continues advancing over time, even more, advanced solutions will come out, which should further help improve patient care. However, the use of new medical solutions must be approved by a doctor before being used on a patient.

Continue reading here:
What Are New Medical Solutions That Can Help Treat Patients? - iLounge

Cell and Gene Therapy Market to reach US$ 47,095.2 Mn by end of 2028, Says Coherent Market Insights – PRNewswire

SEATTLE, Nov. 18, 2021 /PRNewswire/ -- According to Latest Report, The global cell and gene therapy marketis estimated to account for 47,095.2 Mn in terms of value by the end of 2028.

Genetic mutations can lead to a wide range of serious malfunctions at the cellular level, including diseases such as cancer. These treatments use "living drugs" to repair damaged tissues and replace diseased organs, and they have the potential to cure a wide variety of ailments. In addition to regenerating damaged organs, cell and gene therapy can cure cancer, and the treatment process is fast-paced, with significant progress made in recent years. For the cell and gene therapy industry to reach its full potential, early interaction with payers and regulators is crucial. This will facilitate a fast-tracked clinical trial. While embracing new platform technologies is challenging, early collaboration with other industries will ensure a faster path to market for the new therapies. In addition to this, a play-to-win attitude is critical to success in this field. The success of gene and cell therapies will depend on achieving clinical and research goals.

Request for Sample Copy @https://www.coherentmarketinsights.com/insight/request-sample/2475

Market Drivers

1. Increasing incidence of cancer and other target diseases is expected to drive growth of the global cell and gene therapy market during the forecast period

With growing incidence of cancer and target diseases such as measles and tuberculosis, the adoption of gene and cell therapy has increased. According to the World Health Organization (WHO), in 2019, around 1.4 million people died from tuberculosis worldwide with around 10 million people being diagnosed with the same. According to the same source, in 2018, around 9.6 million died due to cancer with over 300,000 new cases of cancer being diagnosed each year among children aged 0-19 years across the globe. Gene therapy uses genes to treat or prevent disease, where it allows doctors to insert a gene into a patient's cells instead of using drugs or surgery. Therefore, it has the potential to completely treat genetic disorders.

2. Growing investments in pharmaceutical R&D activities are expected to propel the global cell andgene therapy market growth over the forecast period

Key pharmaceutical companies in the market are focused on research and development activities pertaining to gene therapy. Currently, gene therapy is being widely researched for various diseases including cancer, cystic fibrosis, hemophilia, AIDS, and diabetes. For instance, in November 2021, Sio Gene Therapies reported positive interim data for gene therapy trial of Phase I/II of AXO-AAV-GM1 for the treatment of GM1 gangliosidosis, a genetic disorder that progressively destroys nerve cells in the brain and spinal cord.

Market Opportunity

1. Increasing demand for cell and gene therapies can present lucrative growth opportunities

The demand for cell and gene therapies is increasing with growing cases of genetic disorders, chronic diseases, etc. According to the Cystic Fibrosis Foundation (CFF), in the U.S., over 1,000 new cases of cystic fibrosis are diagnosed each year. Moreover, According to the WHO, the number of people with diabetes has increased from 108 million in 1980 to 422 million in 2014. According to the same source, in 2016, around 1.6 million deaths were directly caused due to diabetes. Cell and gene therapies have the potential to treat the aforementioned diseases.

2. Growing regulatory approval can provide major business opportunities

Key companies are focused on research and development activities, in order to gain regulatory approval and enhance market presence. For instance, in March 2021, Celgene Corporation, a subsidiary of Bristol Myers Squibb, received the U.S. Food and Drug Administration (FDA) approval for the first cell-based gene therapy Abecma indicated for the treatment of multiple myeloma.

Buy This Premium Research Now @https://www.coherentmarketinsights.com/insight/buy-now/2475

Market Trends

1. Stem cell therapy

In the recent past, stem cell therapies have gained significant importance across the healthcare sector. Stem cell therapy has the potential to treat tissue damage and have low immunogenicity. Furthermore, it can enhance the growth of new healthy skin tissues, improve collagen production, stimulate hair development after loss, and can be used in the treatment of various diseases including Parkinson's disease, Alzheimer's disease, cancer, spinal cord injury, etc.

2. North America Trends

Among regions, North America is expected to witness significant growth in the global cell and gene therapy market during the forecast period. This is owing to ongoing clinical trials combined with key companies focusing on R&D activities pertaining to cell and gene therapy. Moreover, the presence of key market players such as Thermo Fisher Scientific, Takara Bio Inc., Catalent Inc., and more are expected to boost the regional market growth in the near future.

Competitive Section

Major companies operating in the global cell and gene therapy market are Thermo Fisher Scientific, Merck KGaA, Lonza, Takara Bio Inc., Catalent Inc., F. Hoffmann-La Roche Ltd, Samsung Biologics, Wuxi Advanced Therapies, Boehringer Ingelheim, Novartis AG, and Miltenyi Biotec.

For instance, in July 2021, Minova Therapeutics Inc. entered into a collaboration and license agreement with Astellas Pharma Inc. for the research, development, and commercialization of novel cell therapy programs for diseases caused by mitochondrial dysfunction.

Global cell and gene therapy Market, By Region:

Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/2475

About Us:

Coherent Market Insightsis a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.

Contact Us:Mr. Shah Senior Client Partner Business Development Coherent Market Insights Phone: US: +1-206-701-6702 UK: +44-020-8133-4027 Japan: +81-050-5539-1737 India: +91-848-285-0837 Email: [emailprotected] Website: https://www.coherentmarketinsights.com Follow Us:LinkedIn |Twitter

SOURCE Coherent Market Insights

See the original post here:
Cell and Gene Therapy Market to reach US$ 47,095.2 Mn by end of 2028, Says Coherent Market Insights - PRNewswire

FMQs: Senior Glasgow doctor warns claims doctors act in secret or conceal information could damage public confidence as Andrew Slorance widow claims…

Dr Scott Davidson, deputy medical director at NHS Greater Glasgow and Clyde, refuted claims made in Holyrood on Thursday around the death of Andrew Slorance and warned the allegations could damage the publics confidence in medical care.

The comments came after First Minister Nicola Sturgeon said the Scottish Government would not tolerate cover-ups or secrecy, after Louise Slorance said she had only found out her husband, who was being treated for cancer at Queen Elizabeth University Hospital (QEUH), had picked up a deadly fungal infection after trawling through his medical records.

A separate statement from NHS Greater Glasgow and Clyde said the health board did not recognise the claims being made in relation to Mr Slorances death.

Dr Davidson said: My heart goes out to Mr Slorances wife and loved ones as they continue to mourn his loss. We are reaching out to the family and very much hope they will take up our offer to discuss their concerns.

On some of the wider claims being made, there should be no doubt that as clinicians, our primary aim is to provide professional care and treatment for our patients and support their loved ones.

"We dont act in bad faith or attempt to conceal information and that applies equally across the organisation to all of our staff, both clinical and non-clinical, and to suggest otherwise is not acceptable and has caused considerable upset to all of our hard-working and committed staff.

He added: It is also of concern to us, as clinicians, that this could damage the publics confidence in the quality of care we provide. I hope that by meeting with the family, we can explain in detail the care provided to Mr Slorance, answer any questions they may have and provide some comfort going forward.

Speaking earlier at First Ministers Questions, Ms Sturgeon described Mr Slorance as someone she knew very well and a greatly valued member of the Scottish Government team.

She said the chief operating officer of NHS Scotland had raised the claims with NHS Great Glasgow and Clyde.

Mr Slorance, who was head of the Scottish Governments response and communication unit, went into hospital to be treated for cancer in October last year.

Scottish Labour leader Anas Sarwar described the failings at the hospital as the worst scandal of the devolution era.

Ms Sturgeon said: First of all, I can assure the chamber that I have read Louise's words very closely.

"Firstly, because I will always do that, when relatives of those who have died or received substandard care in our National Health Service, because that's part of my duty. But in this case obviously I have done that because Andrew was someone I knew very well.

"He is deeply missed by everyone who had the privilege of working with him and that certainly includes me.

"I think I first met Andrew on the very first day I served in government back in 2007. He made an exceptional contribution to the Scottish Government and my thoughts are often with his loved ones, in particular his wife and his children.

Read More

"My officials have engaged already this morning with Greater Glasgow and Clyde health board, so that the concerns that have been raised are properly investigated.

"We will do everything possible to ensure his family get the answers that they are seeking and also consider very carefully whether the concerns that have been raised by Louise Slorance have raised wider issues that require to be addressed.

Ms Sturgeon added: The chief operating officer of NHS Scotland has contacted Greater Glasgow and Clyde this morning to start to establish the facts and I've asked for information to be available later today and then we will assess what further steps required to be taken.

"I will not this government will not tolerate cover-ups or secrecy on the part of any health board. Where there are concerns about that we will address those concerns.

During his time in hospital, Mr Slorance tested positive for Covid-19 and another life-threatening infection, both of which his widow believes he contracted while at QEUH.

The 49-year-old had been fighting a rare and incurable cancer mantle cell lymphoma for the previous five years.

Mrs Slorance only discovered the fact her husband had been infected with the common fungus, aspergillus, which can be dangerous if it infects those with a weaker immune system, when she requested a copy of his medical records.

A public inquiry is underway to investigate the construction of the QEUH campus in Glasgow and the Royal Hospital for Children and Young People and Department of Clinical Neurosciences in Edinburgh.

The inquiry was ordered after patients at the Glasgow hospital died from infections linked to pigeon droppings and the water supply, and the opening of the Edinburgh site was delayed due to concerns over the ventilation system.

Mr Sarwar said there was a culture of cover-up, denial, and families being failed in the Queen Elizabeth hospital.

He said: From start to finish, the Queen Elizabeth University Hospital scandal has happened under Nicola Sturgeons watch. She was health secretary when the hospital was commissioned and built.

And she was First Minister when it was opened. So she must answer why, despite everything that has happened, do we still have a culture of cover-up, secrecy and denial with families being forced to take on the system to get the truth?

The Glasgow health board leadership has lost the confidence of clinicians, patients, parents and the public. Given everything that has already happened, and everything that has already been uncovered, why is the leadership still in place?

Mr Sarwar added: Not a single person has been held accountable for the catastrophic errors at this hospital. In any other country in the world, there would be resignations and sackings. But under this government its denial and cover-up.

How many more families have to lose loved ones before anyone is held to account?

A statement from NHS Greater Glasgow and Clyde said: Our thoughts and deepest sympathies remain with the family of Mr Slorance.

"At all times we have been open and honest with the family about the treatment provided and we are reaching out to them to further discuss the issues they have raised. After an initial clinical review, we are confident that the care and treatment provided was appropriate and we do not recognise the claims being made.

Infection control procedures at the QEUH are rigorous and of the highest standard. The hospitals public inquiry is currently underway and we have been providing every support to the inquiry team and will continue to do so.

"We are also providing support to both patients and staff throughout the process.

Mr Slorance, a former journalist, was the first head of media relations for the Scottish Parliament after its creation in 1999 and was Alex Salmonds official spokesman between 2007 and 2010.

In 2012, he joined the governments resilience division as head of the response and communications unit responsible for responding to and planning for major emergencies.

Mr Slorance was first diagnosed with mantle cell lymphoma in 2015, but the disease had recently returned. He had been due to undergo a stem cell transplant, but the procedure was postponed due to the coronavirus pandemic.

He wrote a popular blog about his battle with the disease and raised a significant amount of money for cancer charities most recently a 300-mile cycle challenge, which he undertook just months before his death.

See the original post:
FMQs: Senior Glasgow doctor warns claims doctors act in secret or conceal information could damage public confidence as Andrew Slorance widow claims...